IDEXX Laboratories, Inc. (IDXX)
What changed in recent filings
- Institutions — 1 new · 3 added · 3 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
IDEXX Laboratories, Inc. recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Aug 4, 2026Revenue +9.7% YoY · EPS $4.27Released before the open: Aug 3 close → Aug 4 close, the stock moved +3.6% · over the same window, market +1.8% · sector -0.2%
- 26Q1Released May 5, 2026Revenue +14.3% YoY · EPS $3.47Released before the open: May 4 close → May 5 close, the stock moved +0.0% · over the same window, market +0.8% · sector -0.2%
- 25Q4Released Feb 2, 2026Revenue +14.3% YoY · EPS $3.09Released before the open: Jan 30 close → Feb 2 close, the stock moved -4.6% · over the same window, market +0.5% · sector +0.5%
- 25Q3Released Nov 3, 2025Revenue +13.3% YoY · EPS $3.40Released before the open: Oct 31 close → Nov 3 close, the stock moved +14.8% · over the same window, market +0.2% · sector -0.6%
The next earnings release is estimated around Nov 2, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding IDEXX Laboratories, Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 2 → 2026 Q2: 7 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold IDEXX Laboratories, Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- Fundsmith3.93% of portfolio · held as of 2019 Q1 or earlier
- National Pension Service (Korea)0.04% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.13% of portfolio · since 2019 Q2
- Bridgewater Associates0.07% of portfolio · since 2020 Q3
- Harris Associates (Oakmark)under 0.01% of portfolio · since 2025 Q3
- Point72 Asset Management0.15% of portfolio · since 2025 Q4
- Baillie Gifford & CoNew this quarter0.17% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
IDEXX Laboratories, Inc. is classified under the Biotech & Health sector. See peers below.
IDEXX Laboratories, Inc. key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
IDEXX Laboratories, Inc. vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
ETFs holding IDEXX Laboratories, Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
IDXX on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
IDXX FAQ
What is IDEXX Laboratories, Inc. (IDXX)?
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.
What sector is IDEXX Laboratories, Inc. in?
IDEXX Laboratories, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are IDEXX Laboratories, Inc.'s key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 12.8%, Operating margin 35.0%, Net margin 25.0%, ROE 66.0%, Debt-to-equity 0.19x. Definitions and interpretation are available on Stocklore.
Where can I analyze IDEXX Laboratories, Inc. (IDXX) stock?
On Stocklore you can see IDXX's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.